CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance.

Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers. Real-world zanubrutinib treatment patterns in ...

Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: A TriNetX-based retrospective cohort study from 2000-2025. Propensity ...

Physical activity significantly improves quality of life and reduces symptom burden in CLL patients, yet only 24.6% meet recommended activity levels. Treatment-naïve patients are more likely to meet ...